Naia Limited is an international drug development company with subsidiaries advancing clinical‑stage compounds for SBS, NASH and Type 2 diabetes. Its operating subsidiary Naia Rare Diseases holds in‑licensing agreements with Amunix Operating Inc. for GLP‑1 and GLP‑2 XTEN™ receptor agonist candidates and a licensing agreement with Cedars‑Sinai Medical Center (Los Angeles) for a GLP‑1 use patent aimed at SBS. A second subsidiary, Naia Metabolic, is developing clinical compounds for Type 2 diabetes and NASH. The company intends to use new financing to continue investing in its subsidiaries and their portfolio of therapeutic approaches, including a program focused on the orphan indication SBS. Naia’s management is led by co‑founder, chairman and CEO H. Daniel Perez, M.D. Its operating structure includes a Cayman Island‑based management company and several holding companies focused on developing like assets.

Total raised

$5M

Funding rounds

1

Latest round

Series A

Latest activity

Oct 2015